Data layers Raw facts Calculated Model prediction AI interpretation

Company Overview

Stock NamePa Gooddoctor
Stock Code01833
Company Full NameTo be extracted
IndustryHealthcare
Principal Activities我們是中國互聯網醫療健康市場的先行者,通過移動平台提供在線醫療健康服務,包括家庭醫生服務、消費型醫療服務、健康商城和健康管理和互動。
Listing Date2018-05-04
Listing Rules EraOld Rules
Listing Rules ChapterTo be extracted
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)中國上海市凱濱路166號上海平安大廈B座16至19樓
Business Address (Hong Kong)香港皇后大道中99號長江中心53樓5301室
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitepahtg.com
Share Registrar香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited)
Registrar Contact(852)2862 8628
A-Share/US Dual ListingNo

Offering Information

Offering Mechanism Mechanism A
Offer PriceHK$ 54.80 / shares
Offer Price RangeTo be extracted
Lot Size100 shares
Entry ThresholdTo be extracted
Par ValueTo be extracted
Offer Period2018-04-23 to 2018-04-26
Global Offering Shares160,094,200 shares
HK Public Offer Shares (Initial)10,406,200 shares (6.5%)
Public Offer Lots (Initial)104,062lots (Pool A52,031lots,Pool B52,031lots)
International Placing Shares (Initial)149,688,000 shares (93.5%)
Offer Ratio~6.5%
Total Shares Post-IPO1,067,294,200 shares
Greenshoe (Over-allotment Option)Yes
Stabilizing Manager (Greenshoe)To be extracted
Cornerstone Share49.2%
Clawback TiersTo be extracted
Reallocation OptionYes
Total Global Offering SizeHK$ 8,773,162,160

Stock Connect Inclusion Analysis

HK Market Cap HK$ 19.38B
Analysis Result Already included in Stock Connect (both)

Valuation & Financials

Market Cap (at Offer Price)To be extracted
Pre-IPO Valuation (Last Round)Not disclosed
P/E RatioNot disclosed
Profit/Loss Status虧損人民幣1,001.6百萬元
Period-End Cash Balance人民幣4,594.6百萬元
Listing ExpensesTo be extracted
Listing Expenses / Funds RaisedTo be extracted
Total Pre-IPO InvestmentTo be extracted

Financial Data

Unit: '000 RMB
Income Statement
Item 201520162017
Revenue 278,690601,4941,868,021
Cost of sales -167,923-347,915-1,255,951
Gross profit 110,767253,579612,070
Other income and gains, net 1,1569,67524,936
Selling and distribution expenses -178,558-781,079-723,556
Administrative expenses -251,474-461,058-710,665
Operating profit -323,103-740,045-996,425
Net finance costs -377-15,251-164
Share of associates and JVs -228-2,919-4,646
Profit before tax -323,708-758,215-1,001,235
Income tax expense 00-408
Profit for the year -323,708-758,215-1,001,643
Profit attributable to owners -323,708-758,215-1,001,643
Balance Sheet
Item 201520162017
Cash and cash equivalents 105,1212,721,5374,594,641
Trade and bills receivables 6,809109,027454,456
Inventories 7828806,575
Total current assets 253,0024,039,8175,853,053
Total assets 307,0894,187,6705,972,080
Total current liabilities 417,4991,813,3281,938,074
Total liabilities 417,5431,813,3751,938,118
Total equity -110,4542,374,2954,033,962
Equity attributable to owners -110,4542,374,2954,033,962
Interest-bearing borrowings 30,000550,0000
Cash Flow Statement
Item 201520162017
Net cash from operating activities -44,925-263,072-483,942
Net cash from investing activities -124,425-976,493325,869
Net cash from financing activities 108,7503,617,4722,153,955
Net increase in cash -60,6002,377,9071,995,882
Purchase of PP&E -14,425-98,147-12,068
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
First Day CloseHK$ 54.8
First Day OpenHK$ 57.3
First Day Change-81.53%
First Day Volume68143200.0
First Day Turnover3845500000.0
Use of Proceeds
1、約40%的所得款項凈額用于業務拓展; 2、約30%的所得款項凈額用于為我們潛在投資、收購境內公司及與境內公司的策略聯盟以及我們的海外拓展計劃提供資金; 3、約20%的所得款項凈額,用于研發,包括發展我們的信息基礎設施、在國內外招聘高素質的人工智能專業人士及向人工智能人才提供具競爭力的薪酬方案以及與領先的研究機構及大學加強合作及伙拍行業領先的科技公司進行研究及開發; 4、約10%的所得款項凈額,用于營運資金及一般公司用途。

Underwriting Syndicate

Joint Sponsors (2)
Citigroup Global Markets Asia Limited CE AAA137 J.P. Morgan Securities (Far East) Limited CE AAB026
Overall Coordinators (4)
Citigroup Global Markets Asia Limited CE AAA137 J.P. Morgan Securities (Asia Pacific) Limited CE AAJ321 PING AN SECURITIES (HONG KONG) COMPANY LIMITED CE BMC491 UBS Securities Hong Kong Limited CE BIN466
Joint Bookrunners (10)
建银国际金融有限公司 CE AJO225 中国国际金融香港证券有限公司 CE AEN894 CHINA MERCHANTS SECURITIES (HK) CO., LIMITED CE AAI650 Citigroup Global Markets Asia Limited CE AAA137 中信里昂证券有限公司 CE AAB893 招银国际融资有限公司 CE AVM940 香港上海汇丰银行有限公司 CE AAA523 J.P. Morgan Securities (Asia Pacific) Limited CE AAJ321 PING AN SECURITIES (HONG KONG) COMPANY LIMITED CE BMC491 UBS Securities Hong Kong Limited CE BIN466

Cornerstone Investors

#Investor NameInvestment AmountShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 BlackRock Funds 981,232,360 HKD — 11.18% — 6 months 2018-11-04
2 CapRe基金 588,732,840 HKD — 6.71% — 6 months 2018-11-04
3 GIC Private Limited 784,988,080 HKD — 8.95% — 6 months 2018-11-04
4 Pantai Juara Investments Limited 392,494,040 HKD — 4.47% — 6 months 2018-11-04
5 Swiss Re Direct Investments Company 392,494,040 HKD — 4.47% — 6 months 2018-11-04
6 加拿大退休金计划投资委员会 784,988,080 HKD — 8.95% — 6 months 2018-11-04
7 正大光明控股有限公司 392,494,040 HKD — 4.47% — 6 months 2018-11-04

Directors & Management

PositionChinese nameEnglish Name
Chairman王濤—
Company Secretary林源、陳淳—
No director data available.

Major Shareholders

Major Shareholders & Holdings平安集團(通過安鑫)及樂錦煊為控股股東,緊隨全球發售完成後假設超額配股權未獲行使分別持有約39.27%及39.43%權益;王文君、竇文偉、幫騏鍵、羅先生等透過樂錦煊持有權益;SoftBank Vision Fund持有約6.30%。
About this page

This page shows Pa Gooddoctor (01833) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect